Evidence map›Paper›PMID 36053203›Full record

ArticleJournal of the National Cancer Institute2022

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Galloway and 15 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 15 institutions in 1 country.

Cristina P RodriguezDepartment of Medicine, University of Washington, Seattle, WA, USA.ORCID 0000-0003-3568-2630
Hyunseok KangDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Jessica L GeigerDepartment of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH, USA.
Barbara BurtnessDepartment of Medicine, Yale University, New Haven, CT, USA.
Christine H ChungDepartment of Head and Neck-Endocrine Oncology, Moffit Cancer Center, Tampa, FL, USA.
Curtis R PickeringDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carole FakhryDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, USA.
Quynh Thu LeDepartment of Radiation Oncology-Radiation Therapy, Stanford University, Palo Alto, CA, USA.
Sue S YomDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Thomas J GallowayDepartment of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Erica GolemisDepartment of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Alice LiKaiser Permanente Oakland, Oakland, CA, USA.
Jeffrey Shoop
Stuart WongDivision of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Ranee MehraDivision of Hematology/Oncology, Department of Medicine, University of Maryland, Baltimore, MD, USA.
Heath SkinnerDepartment of Radiation Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
Nabil F SabaDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.ORCID 0000-0003-4972-1477
Elsa R FloresDepartment of Molecular Oncology, Moffit Cancer Center, Tampa, FL, USA.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
James M FordDepartment of Medicine, Stanford University, Palo Alto, CA, USA.
Rachel KarchinDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-5069-1239
Robert L FerrisDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.ORCID 0000-0001-6605-2071
Charles KunosNational Institutes of Health, Bethesda, MD, USA.
Jean M LynnNational Institutes of Health, Bethesda, MD, USA.
Shakun MalikNational Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-1472-0263
National Institutes of Health · USUniversity of California, San Francisco · USJohns Hopkins University · USMoffitt Cancer Center · USStanford University · USThe University of Texas MD Anderson Cancer Center · USUniversity of Pittsburgh · USCleveland Clinic · USEmory University · USFox Chase Cancer Center · USKaiser Permanente Oakland Medical Center · USMedical College of Wisconsin · USUniversity of Maryland, Baltimore · USUniversity of Washington · USYale University · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016672NCI NIH HHS U10 CA180820
6 · The paper itself

Abstract

TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus-negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network.

Indexed as

Head and Neck NeoplasmsPapillomavirus InfectionsGenes, p53HumansMutationSquamous Cell Carcinoma of Head and NeckTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID36053203
PMCPMC9745425
OpenAlexW4294339105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.